These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 18682509)

  • 21. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
    Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
    Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
    Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
    Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
    Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
    Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
    Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.
    Li R; Liu J; Li Q; Chen G; Yu X
    Tumour Biol; 2016 Mar; 37(3):3987-96. PubMed ID: 26482618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
    Chang L; Wu P; Senthilkumar R; Tian X; Liu H; Shen X; Tao Z; Huang P
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):59-72. PubMed ID: 26109148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive feedback regulation between Akt phosphorylation and fatty acid synthase expression in osteosarcoma.
    Wang H; Luo QF; Peng AF; Long XH; Wang TF; Liu ZL; Zhang GM; Zhou RP; Gao S; Zhou Y; Chen WZ
    Int J Mol Med; 2014 Mar; 33(3):633-9. PubMed ID: 24366211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma.
    Uddin S; Bavi P; Siraj AK; Ahmed M; Al-Rasheed M; Hussain AR; Ahmed M; Amin T; Alzahrani A; Al-Dayel F; Abubaker J; Bu R; Al-Kuraya KS
    Endocr Relat Cancer; 2010 Mar; 17(1):191-202. PubMed ID: 20008098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain A; Assad L; Al-Dayel F; Bavi P; Al-Kuraya KS; Munkarah A
    Int J Cancer; 2010 Jan; 126(2):382-94. PubMed ID: 19621391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
    Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
    Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
    [No Abstract]   [Full Text] [Related]  

  • 34. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway.
    Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y
    Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer.
    Bo J; Mao S; Yang J; Wang L; Zheng J; Zhang C; Song M; Chen S; Liu C
    Phytomedicine; 2024 Sep; 132():155804. PubMed ID: 38943696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.